Sulpiride
Research News and Information

Saturday, November 21, 2009

Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function.

12 Aug 2009 BACKGROUND: Neurotensin (NT) is known to act on dopamine (DA) neurons at the somatodendritic level to regulate cell firing and secondarily enhance DA release. In addition, anatomical and indirect physiological data suggest the presence of NT ... Read more...

Dopaminergic modulation of olfactory bulb processing affects odor discrimination learning in rats.

30 Jul 2009 Olfactory behavioral studies have shown that, when modulated through systemic injections, D1 and D2 receptors have opposing effects on odor discrimination learning. In the present study, cannulated male Sprague-Dawley rats were used to investigate ... Read more...

Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.

6 Jul 2009 BACKGROUND: Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of ... Read more...

Latest indexed articles for 'Sulpiride'

These are the very latest articles for this heading:

• Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function. 12 Aug 2009
• Zuclopenthixol dihydrochloride for schizophrenia. 4 Aug 2009
• Dopaminergic modulation of olfactory bulb processing affects odor discrimination learning in rats. 30 Jul 2009
• Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. 6 Jul 2009
• [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status] 29 Jun 2009
• [Efficiacy of combined eglonil and avestin administration for pharmacocorrection of depressive disorders in women with hypoestrogenic syndrome] 29 Jun 2009
• The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. 29 Jun 2009
• Causal model of insight and psychopathology based on the PANSS factors: 1-year cross-sectional and longitudinal revalidation. 29 Jun 2009
• Chronic tongue ulceration resolved by sulpiride: a report of two cases. 29 Jun 2009
• [(3)H]-YM-09151-2 binding sites in human brain postmortem. 16 Jun 2009
• Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder. Jun 2009
• Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia. 30 May 2009
• Targeting cognition in schizophrenia research: from etiology to treatment. 30 May 2009
• Effects of cannabinoids infused into the dorsal hippocampus upon memory formation in 3-days apomorphine-treated rats. 16 May 2009
• Fluorescent false neurotransmitters visualize dopamine release from individual presynaptic terminals. 5 May 2009
• [The effect of sulpiride on intensity of gastroesophageal reflux] 29 Apr 2009
• Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice. 29 Apr 2009
• Cellular mechanism of the QT prolongation induced by sulpiride. 29 Apr 2009
• Akathisia and second-generation antipsychotic drugs. 29 Apr 2009
• Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. 29 Apr 2009

See a longer list of these articles.

Technical information about 'Sulpiride'

Definition: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)

Chemical name: Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-

Registry Number: 15676-16-1

Descriptor UI: D013469

Alternative terms: Sulpiride; Sulperide; Arminol; Krewel Brand of Sulpiride; Deponerton; Meresa; Vertigo-Meresa; Vertigo Meresa; Dolorgiet Brand of Sulpiride; Desisulpid; Desitin Brand of Sulpiride; Digton; Areu Brand of Sulpiride; Dogmatil; Dolmatil; Sanofi-Synthelabo Brand of Sulpiride; Sanofi Synthelabo Brand of Sulpiride; Allphar Brand of Sulpiride; Eglonyl; Ekilid; Hoechst Brand of Sulpiride; Guastil; Uriach Brand of Sulpiride; Lebopride; Spyfarma Brand of Sulpiride; neogama; vertigo-neogama; vertigo neogama; Hormosan Brand of Sulpiride; Pontiride; Psicofarma Brand of Sulpiride; Psicocen; Centrum Brand of Sulpiride; Sulpitil; Pharmacia Brand of Sulpiride; Sulpivert; Hennig Brand of Sulpiride; Sulpor; Rosemont Brand of Sulpiride; Sulp; Hexal Brand of Sulpiride; Tepavil; Almirall Brand of Sulpiride; Synédil; Erempharma Brand of Sulpiride; Aiglonyl; Fumouzer Brand of Sulpiride;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Dopamine Antagonists; Antidepressive Agents, Second-Generation; Antipsychotic Agents;

Tree Number: D02.065.277.866; D02.241.223.100.120.866;

History Note: 74